Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
about
Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.Anacetrapib as a potential cardioprotective strategy.Synthesis, Biological Evaluation, and Molecular Modeling Study of Substituted Benzyl Benzamides as CETP Inhibitors.Pharmacological Intervention to Modulate HDL: What Do We Target?
P2860
Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Anacetrapib, but not evacetrap ...... pite of marked HDL-C increase.
@en
Anacetrapib, but not evacetrap ...... pite of marked HDL-C increase.
@nl
type
label
Anacetrapib, but not evacetrap ...... pite of marked HDL-C increase.
@en
Anacetrapib, but not evacetrap ...... pite of marked HDL-C increase.
@nl
prefLabel
Anacetrapib, but not evacetrap ...... pite of marked HDL-C increase.
@en
Anacetrapib, but not evacetrap ...... pite of marked HDL-C increase.
@nl
P2093
P50
P1433
P1476
Anacetrapib, but not evacetrap ...... pite of marked HDL-C increase.
@en
P2093
Adelheid Kratzer
Branko Simic
Elena Osto
Hector Giral
J Wouter Jukema
Jose W van der Hoorn
Margot Crucet
Pavani Mocharla
Petia Doycheva
Susan Kühnast
P304
P356
10.1016/J.ATHEROSCLEROSIS.2017.01.011
P577
2017-01-16T00:00:00Z